[Skip to Content]
[Skip to Content Landing]
September 8, 2010

Refinement of Adjuvant Therapy for Pancreatic Cancer

Author Affiliations

Author Affiliations: Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, New York.

JAMA. 2010;304(10):1124-1125. doi:10.1001/jama.2010.1302

Adenocarcinoma of the pancreas is arguably the most challenging of human malignancies. Approximately 43 000 patients will be diagnosed with pancreatic cancer in the United States in 2010, and during this same period approximately 37 000 will die from this malignancy.1 About 15% to 20% of patients (6500-8600) diagnosed each year have localized disease that is amenable to potentially curative surgery.2 Despite such surgery, nearly 85% of patients are destined to experience relapse and die of their disease.3,4 Therefore, adjuvant therapy is an appealing therapeutic option designed to eradicate occult metastatic disease, delay disease recurrence, and enhance overall survival.

First Page Preview View Large
First page PDF preview
First page PDF preview